TECOS, Merck’s Cardiovascular Safety Trial of JANUVIA (sitagliptin), Met Primary Endpoint in Patients with Type 2 Diabetes
Dateline City:
KENILWORTH, N.J.
Findings Published in the New England Journal of Medicine and Presented at the American Diabetes Association Scientific Sessions
Treatment with Sitagliptin Did Not Increase the Risk of Major Adverse Cardiovascular Events in the Primary Composite Endpoint, or Hospitalization for Heart Failure, Compared with Placebo
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced the primary results of the Trial Evaluating
Cardiovascular Outcomes with Sitagliptin (TECOS), a placebo-controlled
study of the cardiovascular (CV) safety of Merck’s DPP-4 inhibitor,
JANUVIA® (sitagliptin), added to usual care in more than
14,000 patients.
Language:
English
Contact:
MerckMedia:Pam Eisele, 267-305-3558orKim Hamilton, 908-740-1863orInvestors:Joe Romanelli, 908-740-1986orJustin Holko, 908-740-1879
Media Capsule:
Please Activate Javascript
!function(d, s, id){var js,fjs=d.getElementsByTagName(s)[0],p=/^http:/.test(d.location)?'http':'https',dt=new Date().getTime();if(!d.getElementById(id))...
Source: Merck.com - Product News - Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News Source Type: news
More News: Cardiology | Cardiovascular | Diabetes | Diabetes Type 2 | Drugs & Pharmacology | Endocrinology | Heart | Heart Failure | Januvia | Merck | Study